Guanidine derivatives as antiviral agents

(19)

(11)

EP 2 617 709 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.12.2022 Bulletin 2022/51

(45)	Mention of the grant of the patent:
	16.11.2022 Bulletin 2022/46

(21)	Application number: 13164504.6

(22)	Date of filing: 26.06.2004

(51)

International Patent Classification (IPC):

A61K 31/15^(2006.01)
A61P 31/16^(2006.01)
A61P 31/12^(2006.01)
A61K 31/4965^(2006.01)
A61K 31/4406^(2006.01)
C07C 279/22^(2006.01)
C07D 241/34^(2006.01)
A61P 11/00^(2006.01)

A61P 31/18^(2006.01)
A61P 31/14^(2006.01)
A61K 31/55^(2006.01)
A61K 31/47^(2006.01)
A61K 31/381^(2006.01)
A61K 31/165^(2006.01)
A61P 1/16^(2006.01)
A61P 31/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/15; A61K 31/381; A61K 31/4406; A61K 31/47; A61K 31/4965; A61K 31/55; C07C 279/22; A61K 31/165; C07D 241/34; A61P 1/16; A61P 11/00; A61P 31/00; A61P 31/12; A61P 31/14; A61P 31/16; A61P 31/18; Y02A 50/30

(54)	Guanidine derivatives as antiviral agents Guanidinderivate als antivirale Agentien Dérivés de guanidine comme agents antiviraux

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

26.06.2003 AU 2003903251
25.07.2003 AU 2003903850
29.08.2003 AU 2003904692
31.05.2004 AU 2004902902

(43)	Date of publication of application:
	24.07.2013 Bulletin 2013/30

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	04737487.1 / 1646371

(73)	Proprietor: Biotron Limited
	Sydney, New South Wales 2000 (AU)

(72)	Inventors:
	Gage, Peter William deceased (AU) Ewart, Gary Dinneen Hackett, Australian Capital Territory 2602 (AU) Wilson, Lauren Elizabeth Ainslie, Australian Capital Territory 2602 (AU) Best, Wayne Gosnells, Western Australia 6110 (AU) Premkumar, Anita Nicholls, Australian Capital Territory 2915 (AU)

(74)	Representative: Høiberg P/S
	Adelgade 12 1304 Copenhagen K 1304 Copenhagen K (DK)

(56)

References cited: :

EP-A1- 0 682 017
EP-A2- 0 744 397
WO-A1-00/21538
WO-A2-97/46226
US-A- 6 025 349

EP-A1- 0 810 205
EP-A2- 0 755 919
WO-A1-99/20599
FR-A- 1 435 379

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2003, NAIK, RAMCHANDRA GANAPATI ET AL: "A process for preparation of novel antiarrhythmic and cardioprotective substituted propenoyl guanidines", XP002698220, retrieved from STN Database accession no. 2003:1007305
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1998, HISANO, ATSUSHI ET AL: "Preparation of guanidine derivatives as Na+/H+ exchange inhibitors and pharmaceutical compositions containing them", XP002698221, retrieved from STN Database accession no. 1998:768072
BREAM J B ET AL: "SUBSTITUTED PHENYLACETYLGUANIDINES: A NEW CLASS OF ANTIHYPERTENSIVE AGENTS", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 25, no. 10, 1975, pages 1477-1482, XP002036120, ISSN: 0004-4172
O. A. MALYUGA ET AL: "Antitubercular activity of guanidine derivatives", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 5, no. 3, 1971, pages 12-16, XP055065158,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).